Drug development has never been this close to making a clinical impact

Poor translatability of traditional in vitro models is a major reason why only 8% of the drugs that show preclinical efficacy progress after Phase I clinical trials. It’s time to rethink convention.

HUB Organoids provide an accurate representation of patient pathobiology, allowing higher-quality drug candidates to advance to clinical trials. HUB Organoids can support decision-making at every step of the drug development pipeline and help you bring life-changing treatments to patients.

Service portfolio

Preclinical services

Leverage the predictive power of HUB Organoids to select the most promising clinical candidates with confidence

discover more

Clinical trials in a dish

Accurately stratify and customize patient treatment with our co-clinical testing platform

learn more

Custom solutions

Innovate novel disease models and assays and bring your research to the next level

discover more

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology


Drug discovery to clinical trials in five years!

Read our Proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.

learn more get a quote


Rene Overmeer, Head of Assay Development and Automation

watch now


Patient-derived organoids predict clinical response: a patient in the lab

download now

HUB Organoids® and Yamaha Motor announce their collaboration combining their proprietary technologies


Application of HUB Organoids in immuno-oncology drug development

download now

Get in touch

Discover the transformative potential of our technology
with a free consultation with an expert


Have any questions?

contact us